In the BioHarmony Drug Report Database
Cedazuridine
Inqovi (cedazuridine) is a small molecule pharmaceutical. Cedazuridine was first approved as Inqovi on 2020-07-07. It is known to target cytidine deaminase. Inqovi’s patents are valid until 2030-08-22 (FDA).
Trade Name
|
Inqovi |
|---|---|
Common Name
|
cedazuridine |
ChEMBL ID
|
CHEMBL3237547 |
Indication
|
|
Drug Class
|
Antivirals, antineoplastics (uridine derivatives) |
Image (chem structure or protein)